Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Lumateperone(click to collapse)
1/4 selected
Lumateperone
Caplyta
Second-Generation Antipsychotic (SGA)
FDA-approved indications
- Schizophrenia in adults
- Bipolar depression (bipolar I or II) in adults — monotherapy or adjunctive with lithium/valproate
- Major depressive disorder in adults — adjunctive with antidepressants
Off-label uses
- Agitation in Alzheimer dementia (Phase 3 trial discontinued but clinical interest remains)
- Treatment-resistant schizophrenia adjunct (clinical experience)
Mechanism5-HT2A antagonist / D2 partial agonist / SERT inhibitor
Half-life~18 hours
Decision GuideWhen to pick each / when to consider an alternative
Lumateperone
Consider when
- Bipolar I or II depression as monotherapy — only SGA FDA-approved for bipolar II depression monotherapy; effect size −0.56 in both BD-I and BD-II trials
- MDD with inadequate response to antidepressants — FDA-approved adjunct (effect sizes −0.56 to −0.61, comparable to cariprazine and brexpiprazole)
- EPS- or akathisia-prone patient — D2 occupancy ~39% at therapeutic dose; akathisia rates numerically lower than placebo in pooled analyses
- Metabolic risk concerns — weight neutral with mean weight loss −2 to −3.2 kg at 6–12 months; minimal glucose and lipid impact
- +1 more
Consider an alternative when
- Patient on strong CYP3A4 inducer (carbamazepine, phenytoin, rifampin, St. John's wort) — exposure reduced 98%; co-administration contraindicated
- Cost is a barrier — brand-only (Caplyta), no generic available
- Moderate or severe hepatic impairment — requires dose reduction to 21 mg (moderate) or 10.5 mg (severe)
- Acute agitation requiring rapid onset or IM formulation — no rapid-acting, no LAI, no liquid, no ODT (most limited formulation portfolio among SGAs)
- +1 more
| Axis | Lumateperone SGA |
|---|---|
| CNS | |
Sedation / somnolence | |